EU Clears Celgene's Abraxane To Treat Pancreatic Cancer

Law360, New York (January 7, 2014, 5:48 PM EST) -- Drugmaker Celgene Corp. said Tuesday that European regulators have greenlighted a mixture involving its drug Abraxane as a new treatment for pancreatic cancer.

The European Commission approved a combination of Abraxane and gemcitabine to treat pancreatic cancer that has spread to other parts of the body. The U.S. Food and Drug Administration approved Abraxane, a drug that has previously been used to treat breast cancer, for a similar use to treat pancreatic cancer in September. Celgene said it will release the drug in the European Union...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.